Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05266222 · ClinicalTrials.gov registry record
Respiratory Virus Sampling and Repository
A clinical trial of COVID-19 and Influenza, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Recruiting
- Registry status
- 20,000
- Enrollment target
- 2
- Study locations
NCT05266222: Recruiting study of COVID-19 and Influenza, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT05266222 is a study of COVID-19 and Influenza that is actively recruiting participants, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 20,000 participants, below the 38,398-participant average among 298 other COVID-19 trials with a reported enrollment target (48% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05266222, a study of COVID-19 and Influenza, is actively recruiting participants, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- RECRUITING
- Registry status
- 20,000 participants
- Enrollment target
- 2
- Study locations
Study Summary
Background: Respiratory viruses, like the flu or COVID-19, cause significant illness and death worldwide. Researchers want to collect samples from people with respiratory virus infections. The samples in this natural history study will be used in future research. Objective: To obtain samples from people with respiratory viruses to learn more about respiratory virus infections and the immune responses against them. Eligibility: People aged 3 and older who have or are suspected to have a respiratory virus infection. Design: Participants will be screened with a medical record review. Participants will give blood samples. Data from their medical records will be collected. Participants will give nose samples. A soft plastic strip will be put into each nostril for a minute. They may also give nose, mouth (back of the throat), or saliva samples using swabs. Participants may receive kits by mail to collect nose and blood samples at home. They will use soft plastic strips to collect nose samples. To collect blood, they will prick their finger and dab a few drops of blood on four plastic tips. If a participant is in the hospital, air samples may be collected in their room. Participation will last for up to 2 years. After 2 years, participants may be asked for their consent again to give new samples and new medical data.
Primary Outcome
To isolate human respiratory virus specimens and maintain them in a repository for future use in laboratory assays, animal experiments, development of challenge viruses, and development of vaccines, described in a separate protocol.
Study Locations (2)
Maryland
- National Institutes of Health Clinical Center - Bethesda
- NIH Building 33 (NIAID) - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20,000 participants |
| Start Date | 2022-08-11 |
| Est. Completion | 2031-12-31 |
What NCT05266222 shows while recruiting
NCT05266222 is an observational study that tracks outcomes without assigning an intervention. Its 20,000 participants enrollment target places it among the larger protocols in the corpus, below the 38,398-participant average among 298 other COVID-19 trials with a reported enrollment target (48% lower).
The record links to 2 conditions, with COVID-19 appearing as the primary indexed condition, and to 0 interventions.
NCT05266222 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT05266222 about?
NCT05266222 is a clinical study titled "Respiratory Virus Sampling and Repository". Background: Respiratory viruses, like the flu or COVID-19, cause significant illness and death worldwide. Researchers want to collect samples from people with respiratory virus infections. The samples in this natural history study will be used in future research. Objective: To obtain samples from...
What is the current status of trial NCT05266222?
This trial is currently recruiting. The enrollment target is 20,000 participants. The study started on 2022-08-11. Estimated completion is 2031-12-31.
What conditions does trial NCT05266222 study?
This clinical trial studies the following conditions: COVID-19, Influenza.
Who is sponsoring clinical trial NCT05266222?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05266222 being conducted?
This trial has 2 study locations across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05266222's enrollment target sits among peer trials
20,000 17th of 298 higher than 282 of 298 other COVID-19 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other COVID-19 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
CArdiac REhabilitation for Building Exertional heArt Rate for Chronotropic Incompetence in Long COVID-19
RECRUITING · NA
-
Arginine Replacement Therapy in COVID-19
RECRUITING · Phase 2
-
A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
RECRUITING · Phase 2
-
Cardiac Magnetic Resonance Tissue Characterization in COVID-19 Survivors
RECRUITING
-
COVID-19 Health Adjustments in Nutrition, General Wellness, and Exercise
RECRUITING
-
The Impact of COVID-19 on Maternal and Neonatal Outcomes
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00271180 · 20,000 participants
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
- NCT00830557 · 20,000 participants
Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic Disorders
- NCT00900471 · 20,000 participants
Collection and Storage of Tissue Samples From Patients Undergoing Surgery For Suspected Solid Tumors
- NCT02735707 · 20,000 participants · Phase 3
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI